Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
estimated completion

Description

Summary

Main Objective of this study is to examine long-term safety of nivolumab in participants on treatment and in follow up.

Official Title

Pan-Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab

Keywords

Cancer Nivolumab Nivolumab Dose 1 Nivolumab Dose 2

Eligibility

You can join if…

Open to people ages 18 years and up

-

  • Signed Written Informed Consent
  • Participants who have completed treatment with nivolumab, progressed on prior nivolumab treatment or discontinued nivolumab due to toxicity in the Parent Study are not eligible to receive nivolumab in this study. These participants may be enrolled for safety and survival follow-up only.
  • Participant is eligible for nivolumab treatment as per the Parent Study, and/or Investigator assessed clinical benefit, or
  • Participant is in or has completed the follow-up phase of the Parent Study i) Participant has completed or discontinued treatment, or ii) Participant has progressed on treatment, and/or iii) Participant is on subsequent therapy

You CAN'T join if...

-

  • Participant is not eligible for nivolumab treatment as per the Parent Study
  • Participants not receiving clinical benefit as assessed by the Investigator (participant is still eligible for study if entering survival follow-up only)
  • Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant
  • Participants in survival follow-up have no exclusion criteria.

Locations

  • UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Melanoma Center accepting new patients
    San Francisco California 94143 United States
  • Local Institution withdrawn
    San Francisco California 94115 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bristol-Myers Squibb
Links
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting Investigator Inquiry Form FDA Safety Alerts and Recalls
ID
NCT03899155
Phase
Phase 2
Study Type
Interventional
Last Updated